Evidence for dopamine as an inhibitor of vasoprotein release in man.
The effect of dopamine on vasopressin release was studied by the infusion of L-Dopa, a dopamine precursor that crosses the blood-brain barrier. L-Dopa suppressed resting levels of vasopressin and inhibited the rise of vasopressin produced by head-up tilt. Carbidopa, a decarboxylase inhibitor that does not cross the blood-brain barrier blocked the action of L-Dopa. These results suggest that dopamine inhibits the release of vasopressin, either by an action at pituitary level or at the median eminence of the hypothalamus.
D000328:Adult; D001127:Arginine Vasopressin / Q000097:blood / Q000378:metabolism*; D001794:Blood Pressure / Q000187:drug effects; D002230:Carbidopa / Q000494:pharmacology; D003864:Depression, Chemical; D004298:Dopamine / Q000502:physiology*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007980:Levodopa / Q000494:pharmacology; D008297:Male; D011187:Posture; D012636:Secretory Rate / Q000187:drug effects
D001127:Arginine Vasopressin; D007980:Levodopa; D002230:Carbidopa; D004298:Dopamine